Walgreens Children Glycerin

Description

The product is identified by the SPL Code 34089-3 and is associated with a product label effective as of October 6, 2014. The media type for the product representation is an image in JPEG format. The reference for this product is documented as "12 ct. WG Ped Gly Supp.jpg."

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. The precise indications and usage details are not explicitly stated in the provided information.

Healthcare professionals are advised to consult relevant clinical resources and guidelines to determine appropriate applications of this drug in practice. Further information regarding teratogenic and nonteratogenic effects is not available in the current data set.

Dosage and Administration

For children aged 2 to under 6 years, the recommended dosage is to carefully insert 1 suppository well into the rectum. The suppository should be retained for a minimum of 15 minutes to ensure effective laxative action; it is not necessary for the suppository to melt to achieve this effect. The maximum allowable dosage is 1 suppository per day, unless otherwise directed by a healthcare professional.

For children under 2 years of age, it is advised to consult a doctor before administration.

Contraindications

The use of laxative products is contraindicated for periods exceeding one week unless directed by a healthcare professional. Prolonged use may lead to potential complications, including dependency or altered bowel function.

Warnings and Precautions

For rectal use only. Healthcare professionals should advise caregivers that the use of this product may result in rectal discomfort or a burning sensation in the child.

In the event of accidental ingestion, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately.

Laxative products should not be used for longer than one week unless specifically directed by a physician. Prior to administration, it is essential to consult a healthcare provider if the child presents with any of the following conditions: stomach pain, nausea, vomiting, or a sudden change in bowel habits lasting more than two weeks.

Side Effects

Patients using this product may experience rectal discomfort or a burning sensation, particularly when administered rectally. These reactions are important to consider during treatment.

It is advised that caregivers consult a doctor prior to use if the child exhibits any of the following conditions: stomach pain, nausea, vomiting, or a sudden change in bowel habits lasting more than two weeks. These precautions are essential to ensure the safety and well-being of the child during the use of this product.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Walgreens Children Glycerin (glycerin suppository). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 2 to under 6 years may be administered 1 suppository, or as directed by a healthcare professional. For children under 2 years, consultation with a doctor is advised prior to use. It is important to insert the suppository well up into the rectum, as it need not melt completely to produce a laxative effect.

Healthcare professionals should advise caregivers not to exceed 1 suppository daily or the dosage directed by a physician. Additionally, laxative products should not be used for longer than 1 week unless specifically directed by a healthcare provider. Caregivers should be aware that the use of this product may result in rectal discomfort or a burning sensation in pediatric patients.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in the absence of established safety profiles. Women of childbearing potential should be counseled on the importance of effective contraception during treatment.

Lactation

Lactating mothers should consult a doctor before using this product. There is a potential for excretion in breast milk, and the effects on nursing infants are not well studied; therefore, caution is advised.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring hemodynamic stability. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous monitoring and supportive care remain the cornerstone of managing overdose situations until the patient stabilizes or further treatment is indicated.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

Postmarketing experience has indicated that the use of this product may be associated with reports of rectal discomfort or a burning sensation in pediatric patients. These events have been documented through voluntary reporting and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event of swallowing the medication, patients should seek medical help or contact a Poison Control Center immediately.

Patients should be informed that laxative products should not be used for longer than one week unless directed by a healthcare professional. It is important for patients to consult with their doctor before using this product if their child experiences any of the following conditions: stomach pain, nausea, vomiting, or a sudden change in bowel habits lasting more than two weeks.

Storage and Handling

The product is supplied in a tightly closed container to maintain integrity and prevent contamination. It is essential to store the product in a cool, dry place, avoiding exposure to excessive heat to ensure optimal stability and efficacy. Proper handling should be observed to maintain the quality of the product throughout its shelf life.

Additional Clinical Information

The route of administration for the product is rectal. For children aged 2 to under 6 years, the recommended dosage is to carefully insert one suppository well into the rectum and retain it for 15 minutes; it is noted that the suppository need not melt to produce a laxative effect. Clinicians should advise not to exceed one suppository daily unless directed by a physician. For children under 2 years of age, consultation with a doctor is required before administration.

Patients may experience rectal discomfort or a burning sensation while using this product. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Walgreens Children Glycerin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)